



Confidential when completed										
PERSON	N REPORTING	3								
Health Au	uthority: 🔲 F	HA □ IHA	□ VIHA □	NHA □\	/CH					
Name:	Last	First								
Phone:										
Email:										
Date repo	Date report received by health authority:									
			•							
A. CLIE	NT INFORMA	TION								
Panorama	a Investigation II	D			PA	ARIS Clier	t ID			
Name										
Alternate	Last Name(s)		First Date of	of Birth		Λ	PHN			
Home Ad	droop			City	YYYY/M	M/DD	Postal Code	^		Drovingo
nome Au	uress			City				e 		Province
Phone (ho	me/office/cell)		Phone (home/off	fice/cell)			Email			
What gen	der does the cli	ent identify with?	(check all that	apply)			•			
☐ Man	ı	☐ Woman	☐ Tra	ansgender			Non-binary		☐ Unsure/Que	estioning
□ Му	gender is:						Prefer not to	answer		
What sex is listed on the client's BC Services or CareCard?										
Which eth	nnicity/race does	the client self-id	entify with? (ch	eck all that ap	ply)					
☐ Arab	b	☐ Black		Chinese		☐ Filipii	no	☐ Japa	anese	☐ Korean
☐ Latir	n American	☐ South Asi	an □ S	Southeast Asia	ın	☐ West	Asian	☐ Whi	te	
☐ Othe	er, <i>specify:</i>			☐ Asi	ked but	unknown	☐ Decl	ined to an	swer	Not assessed
		fy as an Indigend	us person?	☐ Yes	□ No		eclined to ans	swer	☐ Not	t assessed
person,	identifies as Ind is client: all that apply)	· ·	First Nations	☐ Inuit	☐ Mét	is 🗆 A	sked but unkr	nown \square	Declined to answ	ver
	t registered unde s Indian)?	er the Indian Act	of Canada (i.e.,	☐ Yes	□ No	□А	sked but unkr	nown \square	Declined to answ	ver
	t identifies as a f a reserve?	First Nations pers	on, does client	☐ Yes	□ No	□А	sked but unkr	nown \square	Declined to answ	ver
	does live on a renity dose client l						First Nations organization	i		
Is the clie	nt a health care	worker (HCW)?	☐ Yes	□ No	☐ Un	known				
B. CLAS	SIFICATION									
☐ Confir	med	□ Pr	obable		☐ Sus	spect			☐ Not a Case	
See section	on K for classific	cations. Only cor	firmed cases a	and probable		-	results pendi	ng are rep	oortable to BCCDC).

www.bccdc.ca Version Date: 2022_11_03 Page 1 of 7





C. CLINICAL INFORMATION						
Earliest symptom onset date1:			ash/lesion onset, if presen	t:		
YYYY/MM/DD				YYYY/MM/	(DD	
The earliest date reported of a clinically relevant sym Circum and Comments.	-	Na	A alread hout I halm accom	Dealined to Anomer	Not Assessed	
Signs and Symptoms	Yes	No	Asked but Unknown	Declined to Answer	Not Assessed	
Fever						
Headache						
Myalgia (muscle pain)						
Arthralgia (painful joints)						
Fatigue						
Lymphadenopathy (enlarged glands)						
Chills						
Pharyngitis (sore throat)						
Cough						
Conjunctivitis						
Vomiting						
Nausea						
Proctitis (burning, pain, itching, bleeding)						
Diarrhea						
Rash/lesions						
Other, specify:						
If rash/lesions = yes, specify location(s) and number of	of lesions	S.:				
Location of rash/lesions (select all that a						
☐ Anogenital/perianal		П	Hands and palms of hand			
☐ Oral (mouth, lips, oral mucosa including	throat)		Soles of feet			
☐ Eyes			Torso			
☐ Face, excluding eyes, oral and mucosal	surfaces	s 🗆 (Other, specify:			
☐ Limbs (arms, legs)			- · · · , · · · · · · · · · · ·			
Number of lesions						
☐ One lesion ☐ 50-100 lesions						
☐ 2-10 lesions ☐ >100 lesions						
☐ 10-50 lesions ☐ Unknown						
Complications	Yes	No	Asked but Unknown	Declined to Answer	Not Assessed	
Secondary infection (cellulitis, abscess)						
Corneal infection						
Bronchopneumonia						
Sepsis						
Encephalitis						
Ulcerative lesion with delayed healing						
Myocarditis						
Other, specify:					П	

www.bccdc.ca Version Date: 2022_11_03 Page 2 of 7





D. CLINICAL PRESENTATION AT TIME OF REPORTING							
Highest impact of symptoms							
☐ Did not interfere with daily activities ☐ Interfered with, but did not prevent daily activities							
☐ Prevented daily activities ☐ Prevented daily activities, even with symptom management (e.g., pain medication)							
Admitted to hospital due to monkeypox illness	□ Unknown						
Admission date: Discharge da	te:						
YYYY/MM/DD	YYYY/MM/DD						
Admitted to an intensive care unit Yes No Outcome	☐ Unknown						
	If died, date of death:						
☐ Fully recovered ☐ Not yet recovered/recovering ☐ Fatal If died, date of death: ☐ Permanent disability, specify below ☐ Unknown ☐ Other, specify below ☐ Other, specify below							
Specify other outcome or permanent disability:	, specify below						
a contributed but water turnstrying educe	☐ Did not contribute to death/incidental						
☐ Other, specify:	☐ Underlying cause of death ☐ Unknown						
E. MEDICAL RISK FACTORS/HISTORY							
Did the case ever receive a smallpox and/or monkeypox vaccine?							
If yes, specify indication: Previous vaccination history (e.g., as characteristics) 1960-1980, military, or work on smallpox vaccination	□ Pre-exposure propriviaxis since iviav 2022						
□ Post-exposure prophylaxis since May 2							
□ Not aware of vaccine availability □ N	ot eligible (perceived or per guidelines) Contraindication						
If no, indicate why not: Other reason, specify:							
Dose Administered Date	Vaccine Name						
YYYY/MM/DD or approx. YYYY/MM if exact date not known	vaccine Name						
YYYY/MM/DD <u>or</u> approx. YYYY/MM if exact date not known							
YYYY/MM/DD or approx. YYYY/MM if exact date not known							
YYYY/MM/DD <u>or</u> approx. YYYY/MM if exact date not known 1 2	☐ ACAM2000 ☐ Imvamune ☐ Unknown ☐ Other, specify:						
YYYY/MM/DD <u>or</u> approx. YYYY/MM if exact date not known	☐ ACAM2000 ☐ Imvamune ☐ Unknown ☐ Other, specify:						
YYYY/MM/DD <u>or</u> approx. YYYY/MM if exact date not known 1 2	☐ ACAM2000 ☐ Imvamune ☐ Unknown ☐ Other, specify:						
YYYY/MM/DD or approx. YYYY/MM if exact date not known 1 2 Additional details:	□ ACAM2000 □ Imvamune □ Unknown □ Other, specify: □ ACAM2000 □ Imvamune □ Unknown □ Other, specify:						
YYYY/MM/DD or approx. YYYY/MM if exact date not known 1 2 Additional details: Did the case receive antiviral treatment for monkeypox?	□ ACAM2000 □ Imvamune □ Unknown □ Other, specify: □ ACAM2000 □ Imvamune □ Unknown □ Other, specify: □ Yes □ No □ Unknown						
Additional details: Did the case receive antiviral treatment for monkeypox? If yes, which antiviral? Tecovirimat Brincidofovir Cidofovir Does the case have HIV?	□ ACAM2000 □ Imvamune □ Unknown □ Other, specify: □ ACAM2000 □ Imvamune □ Unknown □ Other, specify: Yes No Unknown Unknown Unknown Other, specify: If yes, specify CD4 counts:						
Additional details: Did the case receive antiviral treatment for monkeypox? If yes, which antiviral? Tecovirimat Brincidofovir Cidofovir Does the case have HIV? Yes No Unknown If yes, is the case on antiretroviral therapy? Yes No	□ ACAM2000 □ Imvamune □ Unknown □ Other, specify: □ ACAM2000 □ Imvamune □ Unknown □ Other, specify: □ Yes □ No □ Unknown □ Unknown □ Other, specify:						
Additional details: Did the case receive antiviral treatment for monkeypox? If yes, which antiviral?	□ ACAM2000 □ Imvamune □ Unknown □ Other, specify: □ ACAM2000 □ Imvamune □ Unknown □ Other, specify: Yes No Unknown Unknown Unknown Other, specify: If yes, specify CD4 counts: Unknown Unknow						
Additional details: Did the case receive antiviral treatment for monkeypox? If yes, which antiviral?	□ ACAM2000 □ Imvamune □ Unknown □ Other, specify: □ ACAM2000 □ Imvamune □ Unknown □ Other, specify: Yes No Unknown Unknown Unknown Other, specify: If yes, specify CD4 counts:						
Additional details: Did the case receive antiviral treatment for monkeypox? If yes, which antiviral? Tecovirimat Brincidofovir Cidofovir Does the case have HIV? Yes No Unknown If yes, is the case on antiretroviral therapy? Yes No Unknown Is the case immunocompromised? Yes No Unknown If yes, specify: Due to disease, specify below Due to messpecify details of immunocompromising condition or medication:	□ ACAM2000 □ Imvamune □ Unknown □ Other, specify: □ ACAM2000 □ Imvamune □ Unknown □ Other, specify: □ Yes □ No □ Unknown □ Unknown □ Other, specify: If yes, specify CD4 counts: Unknown Unknown Unknown						
Additional details: Did the case receive antiviral treatment for monkeypox? If yes, which antiviral?	□ ACAM2000 □ Imvamune □ Unknown □ Other, specify: □ ACAM2000 □ Imvamune □ Unknown □ Other, specify: □ Yes □ No □ Unknown □ Unknown □ Other, specify: If yes, specify CD4 counts: Unknown □ Unknown □ Unknown						
Additional details: Did the case receive antiviral treatment for monkeypox? If yes, which antiviral?	ACAM2000 Imvamune Unknown Other, specify: ACAM2000 Imvamune Unknown Other, specify: Yes No Unknown Unknown Unknown Other, specify: If yes, specify CD4 counts: Unknown U						
Additional details: Did the case receive antiviral treatment for monkeypox? If yes, which antiviral?	□ ACAM2000 □ Imvamune □ Unknown □ Other, specify: □ ACAM2000 □ Imvamune □ Unknown □ Other, specify: Yes						
Additional details: Did the case receive antiviral treatment for monkeypox? If yes, which antiviral? Tecovirimat Brincidofovir Cidofovir Does the case have HIV? Yes No Unknown If yes, is the case on antiretroviral therapy? Yes No Unknown Is the case immunocompromised? Yes No Unknown If yes, specify: Due to disease, specify below Due to me Specify details of immunocompromising condition or medication: Is the case currently pregnant or post-partum? Yes No Mondation: If yes, specify: First trimester Second trimester T	ACAM2000 Imvamune Unknown Other, specify: ACAM2000 Imvamune Unknown Other, specify: Yes No Unknown Unknown Other, specify: If yes, specify CD4 counts: Unknown dication, specify below Unknown Unknown Not applicable Other, specify Other, specify						

www.bccdc.ca Version Date: 2022_11_03 Page 3 of 7





G. RISK FACTORS AND EXPOSURE INFORMATION							
In the 21 days prior to onset of illness							
Has the case had contact with anyone presenting similar symptoms; or with a known suspect, probable, or confirmed case of monkeypox, or with contaminated material (body fluids, object, bedding, etc.)?							
If yes, type(s) of contact	☐ Sexual and/or clo	ose intimate contact		☐ Household (e.g	g. sharing a bed, food, common space)		
(check all that apply):	☐ Close contact, ex	xcluding sexual/intim	ate and household	☐ Other, specify	r		
	☐ Household	☐ Workplace	e ſ	☐ School/nursery	☐ Healthcare		
If yes, setting(s) of contact (check all that apply):		•	_	_			
(спеск ан шасарруу).	☐ Nightclub, private party, sauna, or simi		aurant or other [Large event	☐ Transportation		
	☐ Other, specify:						
Earliest possible exposure (YYYY/MM/DD)		•	Latest possible exposure (YYYY/MM/DD)		☐ Ongoing exposure?		
Travel in the 21 days prior t	to onset of illness						
Did the case travel? ☐ Y	′es □ No □ Un	known If ves: □	within BC only	☐ outside BC but w	vithin Canada □ outside Canada		
		•	ation				
Date of Departure YYYY/MM/DD	Date of Return YYYY/MM/DD	(e.g., Province/Te)	Notes		
In the Od days with the con-	4 - 6 111						
In the 21 days prior to onse Has the case had contact with potentially infected animal(s)?	h an infected or	es □ No □ Unkn	own				
potentially infected animal(s)	•		_	□ Form onimals	□ Wild radanta		
If yes, type(s) of animal(s) (check all that apply):	☐ Household pets,	excluding rodents	☐ Pet rodent	☐ Farm animals	s ☐ Wild rodents		
Additional details (e.g. spec	· ·	cluding wild rodents	☐ Captive wildlif	e ☐ Other, specif	y below Unknown		
and frequency of contact, d							
Indicate exposure settings where the case may have reasonably been exposed and acquired infection (check all that apply)							
Exposure setting is based on local public health assessment (consider known presence of monkeypox, likelihood of transmission, time spent at location, activity at that location)							
☐ Acute care setting ☐ Community health care setting ☐ Congregate living setting ☐ Correctional facilit				☐ Correctional facility			
☐ Mass gathering (>1,000 people) ☐ Occupational/workplace		vorkplace	☐ Personal care setting ☐ Recr		☐ Recreational facility		
☐ Sex-on-premises venue ☐ School/nursery/daycare/		//daycare/daycamp	☐ Social event		☐ Transportation		
Restaurant/bar/nightclul	b 🗆 Unknown		☐ Declined to an	nswer			
☐ Other, <i>specify:</i> In the 21 days prior to onset of	of illness did the case ha	ave multiple sexual p	artners?				
☐ Yes ☐ No ☐ Asked b	out unknown Declir	ned to answer No	t assessed	-			
In the 21 days prior to onset of illness did the case have one or more anonymous sexual partners?							
☐ Yes ☐ No ☐ Asked but unknown ☐ Declined to answer ☐ Not assessed Exposure information continues on the next page							

www.bccdc.ca Version Date: 2022_11_03 Page 4 of 7





G. RISK FACTORS AND EXPOSURE INFORMATION continued							
In the 21 days prior to onset of illness							
Indicate methods and locations used for meeting sexual partners (check all that apply)							
□ Bar/ club □ Sex-on-premises venue □ Cruising/ public spaces □ Dating apps/internet □ Friends/family/school/work							
☐ Out of province, specify:	☐ Oth	er, specify:		☐ Unknown	☐ Decli	ned to answer	
☐ Not applicable (e.g., No sexual	partners met in 21	days prior to onset of	of illness)				
Indicate the gender(s) of sexual partr	ner(s) (check all the	at apply)	·				
☐ Woman ☐ Man ☐ No	n-binary person	☐ Unknown or und	determined If	f none of the above,	specify:		
☐ Not applicable (e.g., No sexual	partners in 21 day	s prior to onset of illr	ness)				
Based on public health assessment,	which is most likel	y mode of transmissi	on for this case?	(check one)			
☐ Animal to human transmission	☐ Healthodetails:	care-associated, spe	cify ☐ Trans	smission from mothe	er to child c	during pregnancy or birt	h
☐ Person-to-person via sexual co	☐ Person-to-person via sexual contact ☐ Person-to-person excluding mother-to-child, ☐ Contact with contaminated materials						
☐ Parenteral transmission includir	•	nission in a laboratory	due to	☐ Other, specify:		☐ Unknown	
intravenous drug use and transfusion Based on public health assessment,		al exposure at possible date Ba	sed on public hea	alth assessment, wh	at is the lat	test possible date of mo	ost
of most likely exposure? (YYYY/MM/D	D)	like	ly exposure? (YY	YY/MM/DD)		·	
H. CONTACTS DURING COMM	LINICABILITY P	PERIOD					
During the communicability period		ERIOD					
	. 0						
Has the case had any high risk contacts? ☐ Yes ☐ No ☐ Unknown							
If yes, estimate number of contacts:							
Did the case travel? ☐ Yes ☐ No ☐ Unknown If yes: ☐ within BC only ☐ outside BC but within Canada ☐ outside Canada If high risk contacts outside of BC are identified, please notify BCCDC of identifiable contacts for follow-up in home jurisdiction by emailing							
monkeypoxIJN@bccdc.ca	e identilied, piease	Thomy BCCDC of Ide	enunable contacts	Tor Tollow-up in Hori	ie jūrisaicii	on by emailing	
Has the case had contact with anima	ls? ☐ Yes	☐ No ☐ Unknow	'n				
If yes, type(s) of ☐ Hous animal(s) (check all that	ehold pets, exclud	ing rodents	Pet rodent	☐ Farm ani	mals	☐ Wild rodents	
() (animals, excluding	wild rodents	Captive wildlife	☐ Other, sp	pecify below	w □ Unknown	
Additional details (e.g. specify animal, type and							
frequency of contact,							
date of last contact) I. LABORATORY INFORMATION	NI.						
I. LABORATORT INFORMATIC)N	Collectio	n data				_
Specimen type	•	YYYY/Mi		Lab test	i	Result	
☐ Skin lesion ☐ (Genital swab						
☐ Lesion crust ☐ F	Rectal swab			☐ Monkeypox vir	ıs PCR	☐ Positive	
☐ Oropharyngeal swab ☐ 5	Serum					☐ Negative	
│				☐ Other, specify.		☐ Indeterminate	
☐ Semen							
☐ Skin lesion ☐ (Genital swah						
☐ Losion crust					D0D	☐ Positive	
				☐ Monkeypox viru	us PCR	☐ Negative	
				☐ Other, specify	<i>'</i> :	☐ Indeterminate	
□ Semen	outer, specity.						
☐ Oropharyngeal swab ☐ S ☐ Urine ☐ C ☐ Semen ☐ Skin lesion ☐ C ☐ Lesion crust ☐ F ☐ Oropharyngeal swab ☐ S ☐ Urine ☐ C	Rectal swab Serum Other, specify: Genital swab Rectal swab Serum Other, specify:			☐ Monkeypox virt ☐ Other, <i>specify</i> . ☐ Monkeypox virt ☐ Other, <i>specify</i> .	us PCR	☐ Negative ☐ Indeterminate ☐ Positive ☐ Negative	

www.bccdc.ca Version Date: 2022_11_03 Page 5 of 7





J. NOTES	





K. DEFINITIONS	
Case Definitions	
Confirmed case	A person who is laboratory confirmed for monkeypox virus by detection of unique sequences of viral DNA either by real-time polymerase chain reaction (PCR) and/or sequencing.
Probable case	A person who presents with an unexplained¹ acute rash or lesion(s)² AND Has one or more of the following in the 21 days before symptom onset: • Has an epidemiological link to a probable or confirmed monkeypox case, • Has an epidemiological link to a location/event where transmission of monkeypox is suspected or known to have occurred, • Epidemiological link such as: • face-to-face exposure, including health workers without appropriate personal protective equipment (PPE) • direct physical contact, including sexual contact; or contact with contaminated materials such as clothing or bedding AND Monkeypox virus has not been ruled out by an Orthopoxvirus or monkeypox virus PCR (i.e. laboratory testing is not available).
Suspect case	A person in whom monkeypox virus has not yet been ruled out by a negative <i>Orthopoxvirus</i> or monkeypox virus PCR result who presents with one or more of the following: • An unexplained¹ acute rash² AND has at least one of the following signs or symptoms • Headache • acute onset of fever (>38.5°C) • lymphadenopathy (swollen lymp nodes) • myalgia • back pain • asthenia (profound weakness) • An unexplained¹ acute genital, perianal or oral lesion(s)

- 1. Common causes of acute rash can include varicella zoster, herpes zoster, measles, herpes simplex, syphilis, chancroid, lymphogranuloma venereum, hand-foot-and-mouth disease.
- 2. Acute rash

Monkeypox illness includes a progressively developing rash that usually starts on the face and then spreads elsewhere on the body. The rash can affect the mucous membranes in the mouth, tongue, and genitalia. The rash can also affect the palms of hands and soles of the feet. The rash can last 2 to 4 weeks and progresses through the following stages before falling off:

- Macules
- Papules
- Vesicles
- Pustules
- Scabs
- 3. Reported travel history includes regional, national, or international travel in the 21 days before symptom onset to any area where monkeypox may be reported.

Exposures	
Close contact / Medium-risk contact	Face-to-face contact within 2 metres for at least one hour, AND does not meet the high-risk exposure characteristics.
High-risk contact	Direct contact between a person's skin or mucous membrane and the case's skin lesions, mucosal lesions or bodily fluids without appropriate PPE. Unprotected skin or mucous membrane contact with objects that have been in contact with infectious bodily fluid or lesions (i.e. clothing, bedding, sex toys).
	Any procedure that may generate aerosols from bodily fluids, skin lesions, or dried exudates without the use of respirators (e.g., N95 or equivalent respirators) or a medical masks and other personal protective equipment (e.g., gloves, gowns, and eye protection.

Hospitalization

Any person admitted to a hospital for at least an overnight stay, or with a prolongation of hospitalization, for reasons directly or indirectly related to their monkeypox infection. Includes persons admitted to hospital but without transfer to a ward/unit.

Version Date: 2022_11_03 Page 7 of 7